Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Neurol ; 23(1): 261, 2023 Jul 07.
Article in English | MEDLINE | ID: mdl-37420168

ABSTRACT

BACKGROUND: Anti-N-methyl-d-aspartate "anti-NMDA" receptor encephalitis is one of the most common autoimmune encephalitis for which first- and second-line therapies have been recommended following international consensus. However, some refractory cases do not respond to the first- and second-line therapy and require further immune-modulatory therapies such as intra-thecal methotrexate. In this study, we reviewed six confirmed cases of refractory anti-NMDA receptor encephalitis from two tertiary centers in Saudi Arabia that required escalation of treatment and received a six-month course of intra-thecal methotrexate. The aim of this study was to evaluate the effectiveness of intra-thecal methotrexate as immunomodulatory therapy for refractory anti-NMDA receptor encephalitis. METHODS: We retrospectively evaluated six confirmed cases of refractory anti-NMDA receptor encephalitis who did not improve after first- and second-line therapy and received monthly intra-thecal methotrexate treatment course for six consecutive months. We reviewed patient demography, underlying etiologies, and compared their modified Rankin score prior to receiving intra-thecal methotrexate and six months after completing the treatment. RESULTS: Three of the six patients showed a marked response to intra-thecal methotrexate with a modified Rankin scale of 0-1 at 6-month follow-up. None of the patients experienced any side effects during or after intra-thecal methotrexate treatment, and no flareups were observed. CONCLUSION: Intra-thecal methotrexate may be a potentially effective and relatively safe escalation option for immunomodulatory therapy of refractory anti-NMDA receptor encephalitis. Future studies on intra-thecal methotrexate -specific treatment regimens may further support its utility, efficacy, and safety in treating refractory anti-NMDA receptor encephalitis.


Subject(s)
Anti-N-Methyl-D-Aspartate Receptor Encephalitis , Hashimoto Disease , Humans , Anti-N-Methyl-D-Aspartate Receptor Encephalitis/drug therapy , Methotrexate/therapeutic use , Retrospective Studies , Antibodies , Receptors, N-Methyl-D-Aspartate
2.
eNeurologicalSci ; 24: 100355, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34307923

ABSTRACT

IMPORTANCE: Coronavirus disease 2019 (COVID-19) is a severe acute respiratory syndrome that is caused by a novel coronavirus 2 (SARS-CoV-2). It originated in China late December 2019 and was declared a global pandemic on March 12, 2020. Most reports of COVID-19 cases either presented with neurological manifestations or complications involve adults. Only few cases were reported in pediatric patients. OBJECTIVE: To report COVID-19 pediatric cases with neurological manifestations and identify the wide spectrum of its manifestations. DESIGN SETTING AND PARTICIPANTS: This was a retrospective, observational case series. Data of pediatric patients infected by SARS-CoV-2 presenting with neurological manifestations at King Abdullah Specialized Children Hospital in King Abdulaziz Medical City in Riyadh were collected from May 23 to June 30, 2020. RESULTS: We encountered 5 COVID-19 cases with neurological manifestations. Three patients who were previously healthy had new-onset neurological symptoms. Symptoms and signs included encephalopathy, ataxia, headache, seizure, papilledema, ophthalmoplegia, hyporeflexia, and different clinical spectra, such as Miller Fisher syndrome, meningoencephalitis, and idiopathic intracranial hypertension. Other patients attending our center were incidentally found to be SARS-CoV-2-positive, which caused a delay in the investigations required to reach diagnosis. CONCLUSIONS AND RELEVANCE: Our cases highlight the wide clinical spectrum of neurological manifestations in COVID-19 patients. Given the paucity of information about pediatric COVID-19 cases with neurological symptoms, we here reported these cases to shed light on the association between SARS-CoV-2 and neurological presentation. Moreover, our study indicates that many investigations are being delayed and could affect diagnosis and treatment.

3.
Appl Neuropsychol Adult ; 28(3): 257-268, 2021.
Article in English | MEDLINE | ID: mdl-31215237

ABSTRACT

The objective of this study was to administer line bisection (LB) and symbol cancellation (SC) tasks on a sample of healthy Arabs in Saudi Arabia, to determine if normative performance would differ from that of the Western population. A total of 136 healthy individuals were enrolled. Deviation direction from the veridical center and percentage deviation scores (PDS) were determined for LB. The overall performance on SC was calculated. Differences according to gender, education and age were measured. Out of the 2,287 times lines were bisected, 1025 (44.82%) deviated rightward (p < 0.0001). Mean (SD) PDS showed a rightward bias 1.57(3.4), (p < 0.0001). Rightward deviation odds modestly increased with age (OR 1.04, P 0.038). In SC, 63% started searching from the left and 67.5% used a horizontal strategy. The mean (SD) performance score was 0.468 (0.248) with no significant cancellation asymmetry. Female gender, education, and age significantly associated with performance. No correlation was found between the two tasks (p = 0.09). Line bisection error biases in Arabs are opposite of Western biases. Scanning for symbols started on the left side; however, this was smaller than that seen in existing Western reports. Normative performances are different from Western studies, but similarly influenced by the same demographic variables.


Subject(s)
Arabs , Perceptual Disorders , Attention , Female , Functional Laterality , Humans , Neuropsychological Tests
SELECTION OF CITATIONS
SEARCH DETAIL
...